

A meta-analysis examining the impact of antibiotic prophylaxis on surgical site wound infection during third molar surgery

Zhang Wang¹

Correspondence:

Zhang Wang
Department of Stomatology,
Xinxiang Central Hospital, the
eighth Clinical College of Xinxiang
Medical University, Henan, 453000,
China
zhang80191991@outlook.com

¹ Department of Stomatology,
Xinxiang Central Hospital, the
eighth Clinical College of Xinxiang
Medical University, Henan, 453000,
China

Volume number 2
Issue number 4
Pages 127-134

10.61466/ijcmr2040004

Received: 05.03.2024

Accepted: 18.07.2024

Published: 20.07.2024

Online: 01.08.2024

Abstract

Backgrounds: The meta-analysis aims to estimate the effect of antibiotic prophylaxis (AP) on surgical site wound infection (SSWI) in third molar surgery (TMS).

Methods: Examinations comparing AP to placebo for TMS were utilized in the meta-analysis from various languages that met the inclusion criteria. Using dichotomous random or fixed effect models, the results of these investigations were examined, and the Odd Ratio (OR) with 95% confidence intervals was computed (CIs).

18 examinations from 2001 to 2023 were recruited for the current analysis including 4063 personals with TMS who were in the utilized examinations' starting point.

Results: AP had significantly lower SSWI (OR, 0.46; 95% CI, 0.33-0.65, $p < 0.001$) with no heterogeneity ($I^2 = 1\%$) compared to placebo in personals with TMS.

Conclusions: The examined data revealed that AP had significantly lower SSWI compared to placebo in personals with TMS. Nevertheless, caution should be exercised while interacting with its values since examinations were performed by different surgeons with different skills on different types of personals and the low sample size of numerous of the examinations selected for the meta-analysis.

Keywords: third molar surgery; placebo; antibiotic prophylaxis; surgical site wound infection; antimicrobial

Introduction

The procedure used most frequently in oral surgery and regular dental practices worldwide are the surgical extraction of compressed third molars (TMs). ¹ The most frequent side effects following third molar surgery (TMS) are infection and inflammation linked to bacterial contamination because of the nature and setting of the procedure. ² Postoperative infection affects 2% to 12% of personals. ³ After removal of the mandibular TM, around 1% of individuals may develop severe fascial space cellulitis that necessitates hospitalization. ⁴ Although such severe infections are uncommon, their effects can be costly and incapacitating. ⁵ The use of antibiotic prophylaxis (AP) after TMS has long been debatable in clinical settings. ⁶ Kay produced what appeared to be compelling data about the need for AP for TMS in his thorough examination of the pathophysiology of pericoronitis and problems after TM elimination in the 1960s. ⁷ He demonstrated that a higher rate of personals who had TMS without antibacterial prophylaxis experienced surgical site wound infections (SSWIs). In comparison, the incidence of SSWI decreased in personals who had a single dosage of penicillin before surgery. In individuals with pericoronitis, when a single dosage of penicillin decreased the occurrence of SSWI, the benefit of AP was even more striking. This study was the catalyst for the widespread prescribing of antibiotics for TMS. Even though the value of AP in TMS before or after the procedure was questioned. ⁸ Long-standing misunderstanding in clinical practice has resulted from the contradictory findings of randomized controlled clinical trials (RCTs), with proponents and detractors of AP each offering their supporting data. ⁶ Although the effectiveness, risk of allergic and anaphylactic responses, and potential for drug

resistance have led many to question the wisdom of routine AP, doctors continue to prescribe antibiotics to treat postoperative problems following TMS.⁶ Several published RCTs have exacerbated the debate, with some arguing for and against the efficacy of AP.⁹⁻¹¹ Personals frequently endure a decreased quality of life and loss of productivity as a result of postoperative SSWI, which are supplemented by crippling pain and severe functional impairment.¹² Therefore, clinicians have been looking for a practical means of preventing postoperative problems following TMS for a very long time. The effectiveness of AP in reducing morbidity related to TMS has been the subject of numerous RCTs, but these studies all shared the same flaw: they lacked the statistical power to discern a significant difference between the examination groups. Rarely did a published clinical study have a sample size that allowed for a solid outcome analysis due to its much lower size. A synthetic quantitative analysis of RCTs on the efficiency of AP in TMS was conducted as part of this study. AP did not work to stop surgical problems, according to the null hypothesis. So, the meta-analysis aims to evaluate the effect of AP on SSWI in TMS.

Method

Design of the examination

The meta-analyses were a part of the epidemiological declaration and adhered to a predetermined examination procedure. For data collection and analysis, a wide number of databases, such as OVID, PubMed, the Cochrane Library, Embase, and Google Scholar, were accessed. These databases were used to collect examinations that focused on evaluating and comparing the effect of AP on SSWI in TMS.

Data pooling

Comparing AP and placebo techniques for the management of TMS resulted in SSWI as a main inclusion parameter. During the screening process and the selection of examinations to include, language restrictions were not taken into account. There were no restrictions imposed on the possible sample sizes of the examinations that were recruited. Reviews, editorials, and letters were not included in this synthesis that we have presented, because they do not include an intervention. The entirety of the process of examination identification is illustrated in Figure 1.




Figure 1. Schematic diagram of the examination procedure

Eligibility of included examinations

An investigation of the effects, both positive and negative, that AP and placebo methods have on the clinical outcome of TMS personals was conducted. Only publications that reported the influence of interventions on the occurrence of SSWI were included in the sensitivity analysis. To do sensitivity and subclass analyses, the interventional groups were compared to a wide variety of subtypes.

Inclusion and exclusion criteria

Inclusion criteria:

The criteria for inclusion in the meta-analysis were as follows: a comparison of the outcomes of AP compared to placebo on SSWI in personals with TMS. The expression of the outcome should be in the appropriate output to be included in statistical analysis.

Exclusion criteria:

Examinations that were not comparative in the design were excluded. In addition, letters, books, review articles, and book chapters were also excluded from the current examination.

Identification of examinations

A protocol of search strategies was devised and specified as follows by the PICOS principle, which states: P (population) persons with TMS; AP was the "intervention" or "exposure"; C (comparison): the comparative effectiveness of AP compared with placebo. O (outcome): SSWI; S (design of the examination): the planned examination had no boundaries.

We did a comprehensive search of the databases PubMed, Cochrane Library, Embase, OVID, and Google Scholar up until June 2023 using the keywords and associated phrases specified in Table 1 (Search techniques for different databases). A review was conducted on the titles and abstracts of all of the articles that had been compiled into a reference managing program, as well as any examination that did not correlate the type of treatments with clinical outcomes. Two authors also serve as reviewers to find appropriate examinations.

Table 1. Database Search Strategy for inclusion of examinations

Database	Search strategy
Google Scholar	#1 "third molar surgery" OR "placebo" OR "antimicrobial" #2 "antibiotic prophylaxis" OR "surgical site wound infection" #3 #1 AND #2
Embase	#1 'third molar surgery' /exp OR 'placebo' exp OR 'antimicrobial' #2 'antibiotic prophylaxis'/exp OR 'surgical site wound infection'/ #3 #1 AND #2
Cochrane library	#1 (third molar surgery):ti,ab,kw (placebo):ti,ab,kw (antimicrobial):ti,ab,kw (Word variations have been searched) #2 (antibiotic prophylaxis):ti,ab,kw OR (surgical site wound infection):ti,ab,kw (Word variations have been searched) #3 #1 AND #2
Pubmed	#1 "third molar surgery"[MeSH Terms] OR "placebo" [MeSH] OR "antimicrobial"[All Fields] #2 "antibiotic prophylaxis"[MeSH Terms] OR "surgical site wound infection "[All Fields] #3 #1 AND #2
OVID	#1 "third molar surgery"[All fields] OR "placebo"[All Fields] OR " antimicrobial" [All Fields] #2 "antibiotic prophylaxis"[All fields] OR "surgical site wound infection"[All Fields] #3 #1 AND #2

Screening of examinations

The following criteria were used to reduce the amount of data: examination and subject features presented in a standardized format; the surname of the examination's first author; the period and year of the examination; the country in which the examination was conducted; and the gender; the population type that was recruited for the examinations; the total number of subjects; qualitative and quantitative evaluation methods; demographic data; clinical and treatment characteristics; information sources; outcome evaluations. Two anonymous reviewers looked at the possibility of bias in each examination as well as the quality of the methods used in the examinations that were chosen for further investigation. The methodology of each examination was evaluated separately by two different reviewers.

Statistical analysis

In the current meta-analysis, the Odds Ratio (OR) with a 95% confidence interval (CI) was determined using dichotomous random- or fixed-effect models. The I^2 index, a numeric value between 0 and 100, was computed (percent). $I^2 = 0$ indicates that there is no heterogeneity, whereas higher I^2 values suggest greater heterogeneity. The random effect was used when I^2 was 50% or greater; if I^2 was less than 50%, the choice to use the fixed effect increased.¹³ As indicated previously, subcategory analysis was performed by stratifying the first evaluation into result categories. Publication bias was analyzed quantitatively using Begg's and Egger's tests, and it was deemed present if $p > 0.05$. The p-values were determined using a test with two tails. Using Jamovi 2.3, statistical analyses and graphs were produced.

Results

18 examinations published between 1974 and 2014 were included in the meta-analysis because they fit the inclusion criteria following a review of 2035 relevant examinations.^{9-11, 14-28} Table 2 summarizes the findings of these investigations. 4063 persons with TMS were in the utilized examinations' starting point, 1792 of them were utilizing AP, and 2271 were utilizing placebo. The sample size was 24 to 1222 persons.

AP had significantly lower SSWI (OR, 0.46; 95% CI, 0.33-0.65, $p < 0.001$) with no heterogeneity ($I^2 = 1\%$) compared to placebo in personals with TMS, as revealed in Figure 2.

The quantitative Egger regression test and the visual clarification of the funnel plot did not reveal any evidence of examination bias ($p = 0.86$) as shown in Figure 3. However, most of the involved examinations were found to have poor practical quality and no bias in selective reporting.




Figure 2. The effect's forest plot of the AP compared to placebo on SSWI in personals with TMS

Table 2. Characteristics of examinations

Study	Country	Total	AP	Placebo
Curran, 1974 ¹⁴	Canada	68	33	35
Bystedt, 1980 ¹⁵	Sweden	140	80	60
Mitchell, 1986 ¹⁶	Germany	50	25	25
Lombardia, 1987 ¹⁷	Spain	479	44	435
Happonen, 1990 ¹⁸	Finland	136	91	45
Monaco, 1999 ¹⁹	Italy	141	66	75
Bulut, 2001 ²⁰	Turkey	60	30	30
Martínez Lacasa, 2003 ⁹	Spain	150	75	75
Poeschl, 2004 ²¹	Austria	528	356	172
Arteagoitia, 2005 ¹⁰	Spain	490	231	259
Graziani, 2005 ¹¹	Italy	30	20	10
Halpern, 2007 ²²	USA	118	59	59
Monaco, 2009 ²³	Italy	59	32	27
Siddiqi, 2010 ²⁴	New Zealand	200	100	100
López-Cedrún, 2011 ²⁵	Spain	79	39	40
Pasupathy, 2011 ²⁶	India	89	60	29
Bortoluzzi, 2013 ²⁷	Brazil	24	12	12
Lee, 2014 ²⁸	Korea	1222	439	783
	Total	4063	1792	2271




Figure 3. The funnel plot of the AP compared to placebo on SSWI in personals with TMS

Discussion

18 examinations from 1974 to 2014 were recruited for the current analysis including 4063 personals with TMS in the utilized examinations' starting point, 1792 of them were utilizing AP, and 2271 were utilizing the placebo.^{9-11, 14-28} The examined data revealed that AP had significantly lower SSWI compared to placebo in personals with TMS. Nevertheless, caution should be exercised while interacting with its values since examinations were performed by different surgeons with different skills on different types of personals and the low sample size of numerous of the examinations selected for the meta-analysis (8 out of 18 ≤ 100 personals).

Since oral surgery is always performed in a clean, contaminated environment with a high concentration of bacteria, and since postoperative problems are frequently brought on by bacterial contamination and infections, it would seem reasonable to prescribe antibiotics to prevent and reduce the frequency of postoperative problems. On the other hand, there is no agreement on how antibiotics should be administered in TMS since the occurrence of postoperative problems is comparatively low and typically not life-threatening, and multiple underpowered RCTs have yielded contentious findings. The objective of this quantitative assessment of RCTs is to compile all relevant data and offer recommendations for AP in TMS. These clinical relevance findings are possibly not as obvious as their statistical significance in terms of odds ratios. The quality of life and productivity of those who experience TM surgical issues are frequently reduced since they are so painful and incapacitating.²⁹ These problems have financial costs that are unquestionably above those of widely administered antibiotics like amoxicillin. From a cost-effectiveness standpoint, it might be reasonable to recommend preventive antibiotic medication for TMS, but the hazards of probable antimicrobial resistance and severe adverse effects are problematic to assess and cannot be completely dismissed in clinical decision-making.³⁰ The surgeon is ultimately in charge of deciding whether or not to provide AP before TMS. He must assess all probable causes of postoperative problems to determine if the advantages of antibiotic therapy exceed the hazards. As a result of the disappearance of the blood clot in the extraction socket, the site of surgery is not seen as bacterial infection-related.

Age, gender, and surgical trauma are all known risk factors for developing postoperative problems.³¹ Using AP solely in individuals thought to have higher risks of postoperative problems may be beneficial. The timing of the antibiotic treatment is crucial for its ability to reduce surgical problems. To have an impact on bacteria that taint surgical incisions and blood clots, the antibiotic must be present at a therapeutic level at the time of the initial incision and before the operation. This necessitates giving the antibiotic around an hour before surgery.³² The present study's findings supported the preoperative administration of antibiotics as being effective for preventing postoperative problems and the uselessness of postoperative dosing. The most reliable dosage strategy for the prevention of SSWIs was an antibiotic given 30 to 90 minutes before the initial incision and continued for 3 to 5 days after the procedure. Antibiotics given as a single dosage before surgery's impact on postoperative SSWIs was less predictable. An antibiotic dose given one hour before surgery may be the most cost-effective method for removing a TM because the incidence of SSWI was lower (6%) in personals who did not take APs than it was in personals who did. A wide-spectrum antibiotic, which is effective against both aerobic and anaerobic bacteria, and a

narrow-spectrum antibiotic, which is exclusively effective against anaerobic bacteria, were utilized in the majority of the clinical studies that were examined. Although the importance of anaerobic bacteria in postoperative problems has been highlighted,³³ both types of bacteria are found in the oral cavity and in proximity to TMs.³⁴ Numerous aerobic and anaerobic bacteria are extremely susceptible to amoxicillin and other penicillin derivatives in the oral cavity. In TMS, they might be the initial option for AP.³⁴

Despite our efforts to utilize a random effect model to increase the rigor of the statistical analysis and to use subgroup analysis to separate the higher quality studies from the lower quality studies, the results of this study cannot be used as a strict guideline in clinical practice regarding AP in TMS. Although the results of this investigation might be the strongest evidence currently available, a well-planned multicenter RCT is required to draw a firm conclusion. Such a conclusive clinical trial should take into account well-known risk variables like age, gender, and smoking, as well as include a well-defined case inclusion or exclusion criterion, a standard operating procedure for surgical and antimicrobial interventions, and a reliable methodology for outcome assessments.³⁵⁻⁴¹ Limitations of the meta-analysis were as next; there can be an assortment bias because some of the tests that were chosen for the meta-analysis were excluded. Despite this, the omitted study did not meet the requirements for inclusion in the meta-analysis. We also required the information to control if factors like age, gender, and ethnicity affected the outcomes. Reviewing the impact of AP on SSWI in TMS was the examination's main objective. The use of inaccurate or incomplete data from a previous analysis could have increased bias. The individual's nutritional status, together with their race, gender, and age, were probably the root reasons for discrimination. Due to incomplete data and some unpublished studies, values may inadvertently be affected.

Conclusions

The examined data revealed that AP had significantly lower SSWI compared to placebo in persons with TMS. Nevertheless, caution should be exercised while interacting with its values since examinations were performed by different surgeons with different skills on different types of persons and the low sample size of many of the examinations selected for the meta-analysis (8 out of 18 ≤ 100 persons).

References

1. Flick, W.G. *The third molar controversy: framing the controversy as a public health policy issue*. Journal of Oral and Maxillofacial surgery **57**(4): p. 438-444 (1999).
2. Blum, I. *Contemporary views on dry socket (alveolar osteitis): a clinical appraisal of standardization, aetiopathogenesis and management: a critical review*. International journal of oral and maxillofacial surgery **31**(3): p. 309-317 (2002).
3. Chiapasco, M., L. De Cicco, and G. Marrone *Side effects and complications associated with third molar surgery*. Oral surgery, oral medicine, oral pathology **76**(4): p. 412-420 (1993).
4. Yoshii, T., Y. Hamamoto, S. Muraoka, et al. *Incidence of deep fascial space infection after surgical removal of the mandibular third molars*. Journal of infection and chemotherapy **7**(1): p. 55-57 (2001).
5. Kunkel, M., T. Morbach, W. Kleis, et al. *Third molar complications requiring hospitalization*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology **102**(3): p. 300-306 (2006).
6. Piecuch, J.F., J. Arzadon, and S.E. Lieblich *Prophylactic antibiotics for third molar surgery: a supportive opinion*. Journal of oral and maxillofacial surgery **53**(1): p. 53-60 (1995).
7. Kay, L. *Investigations into the nature of pericoronitis—II*. British Journal of Oral Surgery **4**: p. 52-78 (1966).
8. Barclay, J. *Metronidazole and dry socket: prophylactic use in mandibular third molar removal complicated by non-acute pericoronitis*. The New Zealand Dental Journal **83**(373): p. 71-75 (1987).
9. Martínez Lacasa, J., J. Jiménez, V. Ferrás, et al. *A Double Blind, Placebo-Controlled, Randomised, Comparative Phase III Clinical Trial of Pharmacokinetically Enhanced Amoxicillin/Clavulanate 2000/125, as Prophylaxis or as Treatment vs Placebo for Infectious and Inflammatory Morbidity after Third Mandibular Molar Removal (TMR)*. 43rd Annual ICAAC Chicago (2003).
10. Arteagoitia, I., A. Diez, L. Barbier, et al. *Efficacy of amoxicillin/clavulanic acid in preventing infectious and inflammatory complications following impacted mandibular third molar extraction*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology **100**(1): p. e11-e18 (2005).
11. Graziani, F., L. Corsi, M. Fornai, et al. *Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction*. Pharmacological research **52**(6): p. 485-490 (2005).
12. Colorado-Bonnin, M., E. Valmaseda-Castellón, L. Berini-Aytés, et al. *Quality of life following lower third molar removal*. International journal of oral and maxillofacial surgery **35**(4): p. 343-347 (2006).
13. Sheikhabaei, S., T.J. Trahan, J. Xiao, et al. *FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in persons with breast cancer: a meta-analysis of diagnostic accuracy studies*. The oncologist **21**(8): p. 931-939 (2016).
14. Curran, J.B., S. Kennett, and A.R. Young *An assessment of the use of prophylactic antibiotics in third molar surgery*. International journal of oral surgery **3**(1): p. 1-6 (1974).

15. Bystedt, H., C.E. Nord, and A. Nordenram *Effect of azidocillin, erythromycin, clindamycin and doxycycline on postoperative complications after surgical removal of impacted mandibular third molars*. International Journal of Oral Surgery **9**(3): p. 157-165 (1980).
16. Mitchell, D. *A controlled clinical trial of prophylactic tinidazole for chemoprophylaxis in third molar surgery*. British Dental Journal **160**(8): p. 284-286 (1986).
17. Lombardia, G.E. and P.M. Garcia, Gonzalez, Garcia M, *Antimicrobial prophylaxis in surgery of the third molar. Analytic study of postoperative complications*. Archivos de Odonto Estomatologia **3**(3): p. 130-134 (1987).
18. Happonen, R.-P., A.-C. Bäckström, and P. Ylipaavalniemi *Prophylactic use of phenoxymethylpenicillin and tinidazole in mandibular third molar surgery, a comparative placebo controlled clinical trial*. British Journal of Oral and Maxillofacial Surgery **28**(1): p. 12-15 (1990).
19. Monaco, G., C. Staffolani, M.R. Gatto, et al. *Antibiotic therapy in impacted third molar surgery*. European journal of oral sciences **107**(6): p. 437-441 (1999).
20. Bulut, E., S. Bulut, İ. Etikan, et al. *The value of routine antibiotic prophylaxis in mandibular third molar surgery: acute-phase protein levels as indicators of infection*. Journal of oral science **43**(2): p. 117-122 (2001).
21. Poeschl, P.W., D. Eckel, and E. Poeschl *Postoperative prophylactic antibiotic treatment in third molar surgery—a necessity?* Journal of oral and maxillofacial surgery **62**(1): p. 3-8 (2004).
22. Halpern, L.R. and T.B. Dodson *Does prophylactic administration of systemic antibiotics prevent postoperative inflammatory complications after third molar surgery?* Journal of Oral and Maxillofacial Surgery **65**(2): p. 177-185 (2007).
23. Monaco, G., L. Tavernese, R. Agostini, et al. *Evaluation of antibiotic prophylaxis in reducing postoperative infection after mandibular third molar extraction in young persons*. Journal of Oral and Maxillofacial Surgery **67**(7): p. 1467-1472 (2009).
24. Siddiqi, A., J. Morkel, and S. Zafar *Antibiotic prophylaxis in third molar surgery: A randomized double-blind placebo-controlled clinical trial using split-mouth technique*. International journal of oral and maxillofacial surgery **39**(2): p. 107-114 (2010).
25. López-Cedrún, J.L., J.I. Pijoan, S. Fernández, et al. *Efficacy of amoxicillin treatment in preventing postoperative complications in persons undergoing third molar surgery: a prospective, randomized, double-blind controlled study*. Journal of Oral and Maxillofacial Surgery **69**(6): p. e5-e14 (2011).
26. Pasupathy, S. and M. Alexander *Antibiotic prophylaxis in third molar surgery*. Journal of Craniofacial Surgery **22**(2): p. 551-553 (2011).
27. Bortoluzzi, M.C., D.L. Capella, T. Barbieri, et al. *A single dose of amoxicillin and dexamethasone for prevention of postoperative complications in third molar surgery: a randomized, double-blind, placebo controlled clinical trial*. J Clin Med Res **5**(1): p. 26-33 (2013).
28. Lee, J., H. Do, J. Lim, et al. *Correlation of antibiotic prophylaxis and difficulty of extraction with postoperative inflammatory complications in the lower third molar surgery*. British Journal of Oral and Maxillofacial Surgery **52**(1): p. 54-57 (2014).
29. McGrath, C., M. Comfort, E. Lo, et al. *Changes in life quality following third molar surgery—the immediate postoperative period*. British dental journal **194**(5): p. 265-268 (2003).
30. Cunha, B.A. *Antibiotic resistance*. Medical Clinics of North America **84**(6): p. 1407-1429 (2000).
31. Benediktsdóttir, I.S., A. Wenzel, J.K. Petersen, et al. *Mandibular third molar removal: risk indicators for extended operation time, postoperative pain, and complications*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology **97**(4): p. 438-446 (2004).
32. Uçkay, İ., S. Harbarth, R. Peter, et al. *Preventing surgical site infections*. Expert review of anti-infective therapy **8**(6): p. 657-670 (2010).
33. Rajasuo, A., K. Perkki, S. Nyfors, et al. *Bacteremia following surgical dental extraction with an emphasis on anaerobic strains*. Journal of dental research **83**(2): p. 170-174 (2004).
34. Sixou, J.-L., C. Magaud, A. Jolivet-Gougeon, et al. *Microbiology of mandibular third molar pericoronitis: Incidence of β -lactamase-producing bacteria*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology **95**(6): p. 655-659 (2003).
35. Lupi, S.M., G. Olivieri, J. Landini, et al. *Antibiotic Prophylaxis in the Prevention of Postoperative Infections in Mandibular Third Molar Extractions: Systematic Review and Meta-Analysis*. Applied Sciences **11**(20): p. 9449 (2021).
36. Menon, R., D. Gopinath, K. Li, et al. *Does the use of amoxicillin/amoxicillin-clavulanic acid in third molar surgery reduce the risk of postoperative infection? A systematic review with meta-analysis*. International journal of oral and maxillofacial surgery **48**(2): p. 263-273 (2019).
37. Arteagoitia, M.-I., L. Barbier, J. Santamaría, et al. *Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis*. Medicina oral, patologia oral y cirugía bucal **21**(4): p. e494 (2016).

38. Falci, S., E. Galvão, G. de Souza, et al. *Do antibiotics prevent infection after third molar surgery? A network meta-analysis*. International Journal of Oral and Maxillofacial Surgery **51**(9): p. 1226-1236 (2022).
39. Marcussen, K.B., A.S. Laulund, H.L. Jørgensen, et al. *A systematic review on effect of single-dose preoperative antibiotics at surgical osteotomy extraction of lower third molars*. Journal of oral and maxillofacial surgery **74**(4): p. 693-703 (2016).
40. Ramos, E., J. Santamaría, G. Santamaría, et al. *Do systemic antibiotics prevent dry socket and infection after third molar extraction? A systematic review and meta-analysis*. Oral surgery, oral medicine, oral pathology and oral radiology **122**(4): p. 403-425 (2016).
41. Ren, Y.-F. and H.S. Malmstrom *Effectiveness of antibiotic prophylaxis in third molar surgery: a meta-analysis of randomized controlled clinical trials*. Journal of oral and maxillofacial surgery **65**(10): p. 1909-1921 (2007).